Robert Friedman

Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel.

Guidehouse, Inc. provides advisory, consulting, outsourcing, technology, and analytics services. It also offers data and analytics, digital enterprise, operations consulting, revenue cycle, risk and compliance, sustainability solutions, and transformation solutions. The company was founded in 1996 and is headquartered in Chicago, IL.